Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Runners-up.

Hand E, Vogel G, Garber K, Kaiser J, Servick K, Clery D, Service RF, Wadman M.

Science. 2018 Dec 21;362(6421):1346-1351. doi: 10.1126/science.362.6421.1346. Epub 2018 Dec 20. No abstract available.

PMID:
30573611
2.

The Heterogeneity of Global Pediatric Surgery: Defining Needs and Opportunities Around the World.

Garber K, Cabrera CCR, Dinh QL, Gerstle JT, Holterman A, Millano L, Muma NJK, Nguyen LT, Tran H, Tran SN, Shekherdimian S.

World J Surg. 2018 Dec 6. doi: 10.1007/s00268-018-04884-x. [Epub ahead of print]

PMID:
30523395
3.

Preface: Workshop on Pesticide Exposure Assessment Paradigm for Non-Apis Bees.

Bireley R, Borges S, Cham K, Epstein D, Garber K, Hart C, Hou W, Ippolito A, Pistorius J, Poulsen V, Sappington K, Steeger T.

Environ Entomol. 2019 Feb 13;48(1):1-3. doi: 10.1093/ee/nvy134. No abstract available.

PMID:
30508082
4.

From helices to health: undergraduate medical education in genetics and genomics.

Hyland K, Garber K, Dasgupta S.

Per Med. 2018 Nov 29. doi: 10.2217/pme-2018-0081. [Epub ahead of print]

PMID:
30489214
5.

No added sugar: antibody makers find an upside to 'no fucose'.

Garber K.

Nat Biotechnol. 2018 Nov 9;36(11):1025-1027. doi: 10.1038/nbt1118-1025. No abstract available.

PMID:
30412203
6.

Scaling resolution of variant classification differences in ClinVar between 41 clinical laboratories through an outlier approach.

Harrison SM, Dolinksy JS, Chen W, Collins CD, Das S, Deignan JL, Garber KB, Garcia J, Jarinova O, Knight Johnson AE, Koskenvuo JW, Lee H, Mao R, Mar-Heyming R, McFaddin AS, Moyer K, Nagan N, Rentas S, Santani AB, Seppälä EH, Shirts BH, Tidwell T, Topper S, Vincent LM, Vinette K, Rehm HL; ClinGen Sequence Variant Inter-Laboratory Discrepancy Resolution Working Group.

Hum Mutat. 2018 Nov;39(11):1641-1649. doi: 10.1002/humu.23643.

PMID:
30311378
7.

Cancer stem cell pipeline flounders.

Garber K.

Nat Rev Drug Discov. 2018 Oct 12. doi: 10.1038/nrd.2018.157. [Epub ahead of print] No abstract available.

PMID:
30310232
8.

Alnylam launches era of RNAi drugs.

Garber K.

Nat Biotechnol. 2018 Sep 6;36(9):777-778. doi: 10.1038/nbt0918-777. No abstract available.

PMID:
30188543
9.

Predicting impacts of chemicals from organisms to ecosystem service delivery: A case study of endocrine disruptor effects on trout.

Forbes VE, Railsback S, Accolla C, Birnir B, Bruins RJF, Ducrot V, Galic N, Garber K, Harvey BC, Jager HI, Kanarek A, Pastorok R, Rebarber R, Thorbek P, Salice CJ.

Sci Total Environ. 2019 Feb 1;649:949-959. doi: 10.1016/j.scitotenv.2018.08.344. Epub 2018 Aug 28.

PMID:
30179823
10.

Xenophobia as a determinant of health: an integrative review.

Suleman S, Garber KD, Rutkow L.

J Public Health Policy. 2018 Nov;39(4):407-423. doi: 10.1057/s41271-018-0140-1.

PMID:
30177729
11.

Sensitivity analyses for simulating pesticide impacts on honey bee colonies.

Kuan AC, DeGrandi-Hoffman G, Curry RJ, Garber KV, Kanarek AR, Snyder MN, Wolfe KL, Purucker ST.

Ecol Modell. 2018 May 24;376:15-27. doi: 10.1016/j.ecolmodel.2018.02.010.

PMID:
30147220
12.

Assessing health systems in unrecognised states: lessons from the field.

Garber K, Aboulian A, Nalbandian D, Abrahamyan A, Danielyan A, Amirjanian A, Shekherdimian S.

BMJ. 2018 Aug 22;362:k3403. doi: 10.1136/bmj.k3403. No abstract available.

PMID:
30135089
13.

Erratum: Nature Biotechnology's academic spinouts of 2017.

Branca MA, Garber K, DeFrancesco L.

Nat Biotechnol. 2018 Aug 6;36(8):772. doi: 10.1038/nbt0818-772c. No abstract available.

PMID:
30080843
14.

Blood test may predict cancer immunotherapy benefit.

Garber K.

Science. 2018 Jun 29;360(6396):1387. doi: 10.1126/science.360.6396.1387. No abstract available.

PMID:
29954961
15.

A new cancer immunotherapy suffers a setback.

Garber K.

Science. 2018 May 11;360(6389):588. doi: 10.1126/science.360.6389.588. No abstract available.

PMID:
29748264
16.

Cytokine resurrection: engineered IL-2 ramps up immuno-oncology responses.

Garber K.

Nat Biotechnol. 2018 May 9;36(5):378-379. doi: 10.1038/nbt0518-378. No abstract available.

PMID:
29734296
17.

Nature Biotechnology's academic spinouts of 2017.

Branca MA, Garber K, DeFrancesco L.

Nat Biotechnol. 2018 Apr 5;36(4):297-306. doi: 10.1038/nbt.4121. No abstract available.

PMID:
29621217
18.

Tissue-agnostic cancer drug pipeline grows, despite doubts.

Garber K.

Nat Rev Drug Discov. 2018 Apr;17(4):227-229. doi: 10.1038/nrd.2018.6. Epub 2018 Mar 9. No abstract available.

PMID:
29520093
19.

Driving T-cell immunotherapy to solid tumors.

Garber K.

Nat Biotechnol. 2018 Mar 6;36(3):215-219. doi: 10.1038/nbt.4090. No abstract available.

PMID:
29509745
20.

A Framework for a Battlefield Trauma System for Civilians.

Garber K, Stewart BT, Burkle FM Jr, Kushner AL, Wren SM.

Ann Surg. 2018 Jul;268(1):30-31. doi: 10.1097/SLA.0000000000002691. No abstract available.

PMID:
29373367
21.

A framework for linking population model development with ecological risk assessment objectives.

Raimondo S, Etterson M, Pollesch N, Garber K, Kanarek A, Lehmann W, Awkerman J.

Integr Environ Assess Manag. 2018 May;14(3):369-380. doi: 10.1002/ieam.2024. Epub 2018 Feb 19.

PMID:
29271573
22.

First metabolic oncology inhibitor gets FDA green light, with record price tag.

Garber K.

Nat Biotechnol. 2017 Oct 11;35(10):895. doi: 10.1038/nbt1017-895. No abstract available.

PMID:
29020002
23.

Adenosine checkpoint agent blazes a trail, joins immunotherapy roster.

Garber K.

Nat Biotechnol. 2017 Sep 11;35(9):805-807. doi: 10.1038/nbt0917-805. No abstract available.

PMID:
28898225
24.

Attitudes Toward Morbidity and Mortality Conferences Among Medical and Surgical Pediatric Specialists in Armenia.

Rouch JD, Dawes AJ, Garber K, Sukhudyan B, Shekherdimian S.

JAMA Surg. 2017 Dec 1;152(12):1178-1180. doi: 10.1001/jamasurg.2017.2974. No abstract available.

25.

In a major shift, cancer drugs go 'tissue-agnostic'.

Garber K.

Science. 2017 Jun 16;356(6343):1111-1112. doi: 10.1126/science.356.6343.1111. No abstract available.

PMID:
28619894
26.

Industry 'road tests' new wave of immune checkpoints.

Garber K.

Nat Biotechnol. 2017 Jun 7;35(6):487-488. doi: 10.1038/nbt0617-487. No abstract available.

PMID:
28591107
27.

Erratum: Drugging the gut microbiome.

Garber K.

Nat Biotechnol. 2017 May 9;35(5):481. doi: 10.1038/nbt0517-481b. No abstract available.

PMID:
28486466
28.

Mechanistic modeling of insecticide risks to breeding birds in North American agroecosystems.

Etterson M, Garber K, Odenkirchen E.

PLoS One. 2017 May 3;12(5):e0176998. doi: 10.1371/journal.pone.0176998. eCollection 2017.

29.

Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy.

Garber K.

Nat Biotechnol. 2017 Apr 11;35(4):297-298. doi: 10.1038/nbt0417-297a. No abstract available.

PMID:
28398313
30.

A framework for predicting impacts on ecosystem services from (sub)organismal responses to chemicals.

Forbes VE, Salice CJ, Birnir B, Bruins RJ, Calow P, Ducrot V, Galic N, Garber K, Harvey BC, Jager H, Kanarek A, Pastorok R, Railsback SF, Rebarber R, Thorbek P.

Environ Toxicol Chem. 2017 Apr;36(4):845-859. doi: 10.1002/etc.3720. Review.

31.

Worth the RISC?

Garber K.

Nat Biotechnol. 2017 Mar;35(3):198-202. doi: 10.1038/nbt.3810. Epub 2017 Feb 27. No abstract available.

PMID:
28244998
32.

Beyond a Moral Obligation: A Legal Framework for Emergency and Essential Surgical Care and Anesthesia.

Chawla KS, Rutkow L, Garber K, Kushner AL, Stewart BT.

World J Surg. 2017 May;41(5):1208-1217. doi: 10.1007/s00268-016-3866-6. Review.

PMID:
28180984
33.

Weight of evidence evaluation of a network of adverse outcome pathways linking activation of the nicotinic acetylcholine receptor in honey bees to colony death.

LaLone CA, Villeneuve DL, Wu-Smart J, Milsk RY, Sappington K, Garber KV, Housenger J, Ankley GT.

Sci Total Environ. 2017 Apr 15;584-585:751-775. doi: 10.1016/j.scitotenv.2017.01.113. Epub 2017 Jan 24. Review.

34.

Alnylam terminates revusiran program, stock plunges.

Garber K.

Nat Biotechnol. 2016 Dec 7;34(12):1213-1214. doi: 10.1038/nbt1216-1213. No abstract available.

PMID:
27926717
35.

Reassessment of Genomic Sequence Variation to Harmonize Interpretation for Personalized Medicine.

Garber KB, Vincent LM, Alexander JJ, Bean LJH, Bale S, Hegde M.

Am J Hum Genet. 2016 Nov 3;99(5):1140-1149. doi: 10.1016/j.ajhg.2016.09.015. Epub 2016 Oct 27.

36.

Big win possible for Ionis/Biogen antisense drug in muscular atrophy.

Garber K.

Nat Biotechnol. 2016 Oct 11;34(10):1002-1003. doi: 10.1038/nbt1016-1002. No abstract available.

PMID:
27727217
37.

Implementing school based telehealth for children with medical complexity.

Cormack CL, Garber K, Cristaldi K, Edlund B, Dodds C, McElligott L.

J Pediatr Rehabil Med. 2016 Sep 2;9(3):237-40. doi: 10.3233/PRM-160385.

PMID:
27612084
38.

Erratum: No longer going to waste.

Garber K.

Nat Biotechnol. 2016 Aug 9;34(8):888. doi: 10.1038/nbt0816-888b. No abstract available.

PMID:
27504779
39.

Cancer anabolic metabolism inhibitors move into clinic.

Garber K.

Nat Biotechnol. 2016 Aug 9;34(8):794-5. doi: 10.1038/nbt0816-794. No abstract available.

PMID:
27504761
40.

Two pioneering osteoporosis drugs finally approach approval.

Garber K.

Nat Rev Drug Discov. 2016 Jun 30;15(7):445-6. doi: 10.1038/nrd.2016.132. No abstract available.

PMID:
27357010
41.

Variants of uncertain significance in newborn screening disorders: implications for large-scale genomic sequencing.

Narravula A, Garber KB, Askree SH, Hegde M, Hall PL.

Genet Med. 2017 Jan;19(1):77-82. doi: 10.1038/gim.2016.67. Epub 2016 Jun 16.

PMID:
27308838
42.

Bristol-Myers Squibb locks into novel autoimmune strategy.

Garber K.

Nat Biotechnol. 2016 Jun 9;34(6):577-9. doi: 10.1038/nbt0616-577. No abstract available.

PMID:
27281396
43.

No longer going to waste.

Garber K.

Nat Biotechnol. 2016 May 6;34(5):458-61. doi: 10.1038/nbt.3557. No abstract available. Erratum in: Nat Biotechnol. 2016 Aug 9;34(8):888.

PMID:
27153267
44.

Participatory Genomic Testing as an Educational Experience.

Garber KB, Hyland KM, Dasgupta S.

Trends Genet. 2016 Jun;32(6):317-320. doi: 10.1016/j.tig.2016.03.008. Epub 2016 Apr 22. Review.

PMID:
27117243
45.

Natural killer cells blaze into immuno-oncology.

Garber K.

Nat Biotechnol. 2016 Mar;34(3):219-20. doi: 10.1038/nbt0316-219. No abstract available.

PMID:
26963532
46.

Alternative Therapeutic Approach in the Treatment of Oral Pyogenic Granuloma.

Bugshan A, Patel H, Garber K, Meiller TF.

Case Rep Oncol. 2015 Nov 14;8(3):493-7. doi: 10.1159/000441839. eCollection 2015 Sep-Dec.

47.

Participation in the Adoption Mentoring Partnership: Mentors' Experiences of Ethnic Identity.

Garber KJ, French QY, Grotevant HD.

New Dir Child Adolesc Dev. 2015 Dec;2015(150):77-89. doi: 10.1002/cad.20123.

PMID:
26650810
48.

Tumor macrophage target fuels $1.7-billion deal.

Garber K.

Nat Biotechnol. 2015 Dec 9;33(12):1222. doi: 10.1038/nbt1215-1222. No abstract available.

PMID:
26650003
49.

Predictive biomarkers for checkpoints, first tests approved.

Garber K.

Nat Biotechnol. 2015 Dec 9;33(12):1217-1218. doi: 10.1038/nbt1215-1217. No abstract available.

PMID:
26649999
50.

CELL BIOLOGY. Protein 'drops' may seed brain disease.

Garber K.

Science. 2015 Oct 23;350(6259):366-7. doi: 10.1126/science.350.6259.366. No abstract available.

PMID:
26494738

Supplemental Content

Loading ...
Support Center